OR27-3 Long-Term Results from the Phase III LINC 4 Study: Osilodrostat Maintained Normal Mean Urinary Free Cortisol in Patients with Cushing's Disease, with a Favorable Safety Profile

BACKGROUND: Osilodrostat, a potent oral 11β-hydroxylase inhibitor, provided rapid and sustained normalization of mean urinary free cortisol (mUFC) in patients with Cushing's disease (CD) during the 48-week (W) core period of LINC 4 (NCT02697734), and was well tolerated. We report long-term effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Auchus, Richard J, Belaya, Zhanna, Bex, Marie, Feelders, Richard A, Heaney, Anthony P, Paul, Michaela, Pedroncelli, Alberto M, Snyder, Peter J, Turcu, Adina F, Witek, Przemysław, Gadelha, Mônica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Neuroendocrinology and Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625329/
http://dx.doi.org/10.1210/jendso/bvac150.1094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625329/
http://dx.doi.org/10.1210/jendso/bvac150.1094

Ejemplares similares